MX2020008326A - Formas de co-cristales de un analogo de novobiocina y prolina. - Google Patents
Formas de co-cristales de un analogo de novobiocina y prolina.Info
- Publication number
- MX2020008326A MX2020008326A MX2020008326A MX2020008326A MX2020008326A MX 2020008326 A MX2020008326 A MX 2020008326A MX 2020008326 A MX2020008326 A MX 2020008326A MX 2020008326 A MX2020008326 A MX 2020008326A MX 2020008326 A MX2020008326 A MX 2020008326A
- Authority
- MX
- Mexico
- Prior art keywords
- proline
- crystal forms
- novobiocin
- analog
- dimethyltetra
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862627570P | 2018-02-07 | 2018-02-07 | |
| PCT/US2019/016304 WO2019156907A1 (en) | 2018-02-07 | 2019-02-01 | Co-crystal forms of a novobiocin analog and proline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008326A true MX2020008326A (es) | 2020-09-28 |
Family
ID=65444361
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008326A MX2020008326A (es) | 2018-02-07 | 2019-02-01 | Formas de co-cristales de un analogo de novobiocina y prolina. |
| MX2022012856A MX2022012856A (es) | 2018-02-07 | 2020-08-06 | Formas de co-cristales de un analogo de novobiocina y prolina. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012856A MX2022012856A (es) | 2018-02-07 | 2020-08-06 | Formas de co-cristales de un analogo de novobiocina y prolina. |
Country Status (19)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020016205A2 (pt) | 2018-02-07 | 2020-12-15 | Reata Pharmaceuticals, Inc. | Formas cocristalinas de prolina e de análogo de novobiocina |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| CN115181146B (zh) * | 2021-04-02 | 2024-06-04 | 浙江普洛家园药业有限公司 | 一种新生霉素的提取工艺 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013006651A2 (pt) | 2010-09-23 | 2017-07-18 | Nuformix Ltd | composição e cocristal de aprepitante l-prolina |
| TWI542596B (zh) * | 2011-05-09 | 2016-07-21 | 健生藥品公司 | (2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體 |
| CN108640910A (zh) * | 2011-11-25 | 2018-10-12 | 诺弗米克斯技术有限公司 | 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体 |
| EP2602249B1 (en) * | 2011-12-06 | 2015-08-12 | F.I.S. Fabbrica Italiana Sintetici S.p.A. | Synthesis of rosuvastatin by means of co-crystals |
| BR112014019704B1 (pt) * | 2012-02-09 | 2022-05-31 | University Of Kansas | Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo |
| US9556216B2 (en) * | 2012-08-31 | 2017-01-31 | Novartis Ag | 2′-Ethynyl nucleoside derivatives for treatment of viral infections |
| TW201512201A (zh) * | 2013-03-14 | 2015-04-01 | Forum Pharmaceuticals Inc | 化合物的多晶型及鹽類 |
| CA3289739A1 (en) | 2014-06-24 | 2025-11-29 | The University Of Kansas | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers |
| PT3202772T (pt) * | 2014-09-30 | 2020-11-20 | Jiangsu Hengrui Medicine Co | Cristal de um complexo de l-prolina/inibidor do cotransportador de sódio-glicose 2 |
| BR112020016205A2 (pt) | 2018-02-07 | 2020-12-15 | Reata Pharmaceuticals, Inc. | Formas cocristalinas de prolina e de análogo de novobiocina |
-
2019
- 2019-02-01 BR BR112020016205-1A patent/BR112020016205A2/pt unknown
- 2019-02-01 TW TW112106332A patent/TWI868593B/zh active
- 2019-02-01 WO PCT/US2019/016304 patent/WO2019156907A1/en not_active Ceased
- 2019-02-01 KR KR1020207025571A patent/KR102718111B1/ko active Active
- 2019-02-01 MX MX2020008326A patent/MX2020008326A/es unknown
- 2019-02-01 EA EA202091885A patent/EA202091885A1/ru unknown
- 2019-02-01 IL IL315865A patent/IL315865A/en unknown
- 2019-02-01 TW TW108104336A patent/TWI797249B/zh active
- 2019-02-01 TW TW113147071A patent/TWI915111B/zh active
- 2019-02-01 CA CA3090646A patent/CA3090646C/en active Active
- 2019-02-01 PE PE2020001199A patent/PE20211446A1/es unknown
- 2019-02-01 EP EP19705879.5A patent/EP3749675B1/en active Active
- 2019-02-01 CA CA3226385A patent/CA3226385A1/en active Pending
- 2019-02-01 US US16/265,256 patent/US10717755B2/en active Active
- 2019-02-01 IL IL276583A patent/IL276583B2/en unknown
- 2019-02-01 KR KR1020247033920A patent/KR20240155354A/ko not_active Ceased
- 2019-02-01 JP JP2020542665A patent/JP2021512910A/ja not_active Ceased
- 2019-02-01 SG SG11202007530XA patent/SG11202007530XA/en unknown
- 2019-02-01 CN CN201980011980.6A patent/CN112020506B/zh active Active
- 2019-02-01 MY MYPI2020004057A patent/MY209803A/en unknown
- 2019-02-01 AU AU2019217821A patent/AU2019217821B2/en active Active
- 2019-02-01 CN CN202410935084.1A patent/CN118894894A/zh active Pending
- 2019-02-05 AR ARP190100277A patent/AR114245A1/es unknown
-
2020
- 2020-06-05 US US16/894,461 patent/US11401294B2/en active Active
- 2020-08-06 CO CONC2020/0009761A patent/CO2020009761A2/es unknown
- 2020-08-06 MX MX2022012856A patent/MX2022012856A/es unknown
- 2020-08-07 CL CL2020002051A patent/CL2020002051A1/es unknown
-
2022
- 2022-12-05 AU AU2022283638A patent/AU2022283638B2/en active Active
- 2022-12-27 CL CL2022003784A patent/CL2022003784A1/es unknown
-
2023
- 2023-02-13 US US18/168,495 patent/US20240043465A1/en not_active Abandoned
- 2023-10-05 JP JP2023173340A patent/JP2024001167A/ja not_active Withdrawn
-
2024
- 2024-10-25 AU AU2024227646A patent/AU2024227646A1/en active Pending
-
2025
- 2025-10-23 JP JP2025178611A patent/JP2026012851A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ629778A (en) | C-terminal hsp90 inhibitors | |
| CL2022003784A1 (es) | Formas co-cristalinas de un análogo de novobiocina y prolina | |
| ECSP19053616A (es) | N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga | |
| CR20210381A (es) | MOLÉCULA DE UNIÓN AL ANTÍGENO MULTIESPECÍFICA QUE TIENE ACTIVIDAD DE SUSTITUCIÓN DE LA FUNCIÓN DE COFACTOR DEL FACTOR VIII DE COAGULACIÓN DE SANGRE (FVIII) Y FORMULACIÓN FARMACÉUTICA QUE CONTIENE TAL MOLÉCULA COMO INGREDIENTE (Divisional Exp. 2020-0158) | |
| JOP20210154B1 (ar) | مثبطات kif18a | |
| BR112021007902A2 (pt) | Anticorpo anti-cd73, fragmento de ligação ao antigênio e aplicação dos mesmos | |
| EA202092086A1 (ru) | Ингибиторы аргиназы | |
| MX2022005256A (es) | Inhibidores de cd73. | |
| MX2022005775A (es) | Compuestos terapeuticos y metodos de uso. | |
| CR20210442A (es) | ALCOHOLES TERCIARIOS COMO INHIBIDORES DE PI3K-y (Divisional Exp. 2020-0214) | |
| EA201990949A1 (ru) | Сульфоксиалкильные органические нитросоединения и родственные соединения и фармацевтические композиции для применения в медицине | |
| EA202192008A1 (ru) | Lilrb3-связывающие молекулы и варианты их применения | |
| EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
| EP3986873C0 (en) | 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND SIMILAR COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | |
| MA46778A1 (fr) | Composition intranasale comprenant de la bétahistine | |
| EP3903806A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISEASES MEDIATED BY TRPV1 ACTIVITY | |
| FR3075012B1 (fr) | Procede de traitement cosmetique par plasma froid | |
| EP3991727A4 (en) | Composition for treating degenerative brain diseases, containing 2-pentylfuran as active ingredient | |
| EA202191758A1 (ru) | Пептиды для лечения и профилактики диабета и связанных с ним заболеваний | |
| EA201692185A1 (ru) | Пролекарство 1,1'-(1,6-диоксо-1,6-гександиил)бис-d-пролина | |
| CO2020001375A2 (es) | Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico | |
| BR112017015474A2 (pt) | inibidores de bace1 | |
| MA39533A1 (fr) | Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives | |
| CL2011003165A1 (es) | Compuestos derivados de 1-(2-alquil-2,3-dihidro-benzofuran-4-il)-pirrolidin-3-ilaminoacilo; composicion farmaceutica; y su uso para el tratamiento o la prevencion de trastornos melatoninergicos tales como depresion, estres, trastornos del sueño, insomnio, diabetes, enfermedad de parkinson, enfermedad de alzheimer entre otros. | |
| EA202192254A1 (ru) | Fcmr-связывающие молекулы и их применение |